Simvastatin Effects on Inflammation and Platelet Activation Markers in Hypercholesterolemia

BioMed Research International

Volumn 2018, Issue , 2018, Pages

  Barale, Cristina ^a   Frascaroli, Chiara ^b   Senkeev, Rouslan ^a   Cavalot, Franco ^b   Russo, Isabella ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADVANCED GLYCATION END PRODUCT; ARACHIDONIC ACID; CD40 LIGAND; COLLAGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PLATELET DERIVED GROWTH FACTOR BB; RANTES; SIMVASTATIN; VASCULOTROPIN; BIOLOGICAL MARKER; CYTOKINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEMALE; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; HYPERCHOLESTEROLEMIA; IC50; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; MALE; MIDDLE AGED; OXIDATIVE STRESS; PLATELET REACTIVITY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BIOMARKERS; CYTOKINES; E-SELECTIN; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; SIMVASTATIN;

EID: 85055322525     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2018/6508709     Document Type: Article

References (46)

1. C. Baigent, A. Keech, and P. M. Kearney, "Efficacy and safety of cholesterol-lowering treatment: prospectivemeta-Analysis of data from90, 056 participants in 14 randomised trials of statins, " The Lancet, vol. 366, no. 9493, pp. 1267-1278, 2005.
2. J. S. Kanshana, V. Khanna, V. Singh et al., "Progression and Characterization of the Accelerated Atherosclerosis in Iliac Artery of New Zealand White Rabbits: Effect of Simvastatin, " Journal of Cardiovascular Pharmacology, vol. 69, no. 5, pp. 314-325, 2017.
3. F. Chu, M. Wang, H. Ma, and J. Zhu, "Simvastatin Modulates Interaction BetweenVascular SmoothMuscleCell/Macrophage and TNF-Activated Endothelial Cell, " Journal of Cardiovascular Pharmacology, vol. 77, no. 5, pp. 268-274, 2018.
4. E. Diamantis, G. Kyriakos, L. V. Quiles-Sanchez, P. Farmaki, and T. Troupis, "The anti-inflammatory effects of statins on coronary artery disease: An updated review of the literature, " Current Cardiology Reviews, vol. 13, no. 3, pp. 209-216, 2017.
5. S. Kinlay andA. P. Selwyn, "Effects of statins on inflammation in patientswith acute and chronic coronary syndromes, "American Journal of Cardiology, vol. 91, no. 4, 2003.
6. B. Sadowitz, K. G. Maier, and V. Gahtan, "Basic science review: statin therapy part 1: The pleiotropic effects of statins in cardiovascular disease, " Vasc Endovascular Surg, vol. 44, pp. 241-251, 2010.
7. A.M. Kolodziejczyk, M. Targosz-Korecka, andM. Szymonski, "Nanomechanical testing of drug activities at the cellular level: Case study for endothelium-Targeted drugs, " Pharmacological Reports, vol. 69, no. 6, pp. 1165-1172, 2017.
8. A. Saggini, A. Anogeianaki, G. Maccauro et al., "Cholesterol, cytokines and diseases, " International Journal of Immunopathology and Pharmacology, vol. 24, no. 3, pp. 567-581, 2011.
9. V. Lahera, M. Goicoechea, S. G. de Vinuesa et al., "Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: Beneficial effects of statins, " Current Medicinal Chemistry, vol. 14, no. 2, pp. 243-248, 2007.
10. G. Rudofsky, P. Reismann, J. B. Groener et al., "Identical LDL-cholesterol lowering but non-identical effects on NF-B activity: High dose simvastatin vs combination therapy with ezetimibe, " Atherosclerosis, vol. 223, no. 1, pp. 190-196, 2012.
11. A. Blum and R. Shamburek, "The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis, " Atherosclerosis, vol. 203, no. 2, pp. 325-330, 2009.
12. C. Hsu, J. Zhao, S. Lin et al., "Asymmetric Dimethylarginine Limits the Efficacy of Simvastatin Activating Endothelial Nitric Oxide Synthase, " Journal of the AmericanHeart Association, vol. 5, no. 4, 2016.
13. Y. Chen, H. Zhang, H. Liu, and A. Cao, "Mechanisms of simvastatin-induced vasodilatation of rat superior mesenteric arteries, " Biomedical Reports, vol. 5, no. 4, pp. 491-496, 2016.
14. H. Almukhtar, M. J. Garle, P. A. Smith, and R. E. Roberts, "Effect of simvastatin on vascular tone in porcine coronary artery: Potential role of the mitochondria, " Toxicology and Applied Pharmacology, vol. 305, pp. 176-185, 2016.
15. A. Hernandez-Mijares, C. Bañuls, S. Rovira-Llopis et al., "Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hypercholesterolemia, " Atherosclerosis, vol. 247, pp. 40-47, 2016.
16. S. C. Allen and C. D. S. Mamotte, "Pleiotropic and Adverse Effects of Statins-Do Epigenetics Play a Role?" The Journal of Pharmacology and Experimental Therapeutics, vol. 362, no. 2, pp. 319-326, 2017.
17. A. S. Antonopoulos, M. Margaritis, R. Lee, K. Channon, and C. Antoniades, "Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials, "Current Pharmaceutical Design, vol. 18, no. 11, pp. 1519-1530, 2012.
18. C. D. Owens, "Statins and other agents for vascular inflammation, " Journal of Vascular Surgery, vol. 56, no. 6, pp. 1799-1806, 2012.
19. B. W. Wong, A. Meredith, D. Lin, and B. M. McManus, "The Biological Role of Inflammation in Atherosclerosis, " Canadian Journal of Cardiology, vol. 28, no. 6, pp. 631-641, 2012.
20. M. P. Lambert, B. S. Sachais, andM. A. Kowalska, "Chemokines and thrombogenicity, " rombosis and Haemostasis, vol. 97, no. 5, pp. 722-729, 2007.
21. Z. M. Ruggeri and G. L. Mendolicchio, "Adhesion mechanisms in platelet function, " Circulation Research, vol. 100, no. 12, pp. 1673-1685, 2007.
22. L. Badimon, R. Suades, E. Fuentes, I. Palomo, and T. Padŕo, "Role of platelet-derived microvesicles as crosstalk mediators in atherothrombosis and future pharmacology targets: A link between inflammation, atherosclerosis, and thrombosis, " Frontiers in Pharmacology, vol. 7, 2016.
23. J. V. Mitsios, A. I. Papathanasiou, J. A. Goudevenos, and A. D. Tselepis, "The antiplatelet and antithrombotic actions of statins, " Current Pharmaceutical Design, vol. 16, no. 34, pp. 3808-3814, 2010.
24. J. W. N. Akkerman, "From low-density lipoprotein to platelet activation, " The International Journal of Biochemistry & Cell Biology, vol. 40, no. 11, pp. 2374-2378, 2008.
25. L. Puccetti, A. L. Pasqui, M. Pastorelli et al., "Time-dependent effect of statins on platelet function in hypercholesterolaemia, " European Journal ofClinical Investigation, vol. 32, no. 12, pp. 901-908, 2002.
26. R. Fitzgerald and M. Pirmohamed, "Aspirin resistance: effect of clinical, biochemical and genetic factors, " Pharmacology & Therapeutics, vol. 130, no. 2, pp. 213-225, 2011.
27. M. Boncler, P. Gresner, M. Nocun et al., "Elevated cholesterol reduces acetylsalicylic acid-mediated platelet acetylation, " Biochimica et Biophysica Acta (BBA)-General Subjects, vol. 1770, no. 12, pp. 1651-1659, 2007.
28. A. Undas, Z. Siudak, R. Toṕor-Madry, M. Lésniak, andW. Tracz, "Simvastatin administration reduces thromboxane production in subjects taking aspirin: Links between aspirin resistance and thrombin generation, " International Journal of Cardiology, vol. 154, no. 1, pp. 59-64, 2012.
29. B. Luzak, J. Rywaniak, L. Stanczyk, and C. Watala, "Pravastatin and simvastatin improves acetylsalicylic acid-mediated in vitro blood platelet inhibition, " European Journal of Clinical Investigation, vol. 42, no. 8, pp. 864-872, 2012.
30. S. Matetzky, P. Fefer, B. Shenkman et al., "Statins have an early antiplatelet effect in patients with acute myocardial infarction, " Platelets, vol. 22, no. 2, pp. 103-110, 2011.
31. M. T. Santos, M. P. Fuset, M. Ruano, A. Moscardo, and J. Valles, "Effect of Atorvastatin on Platelet Thromboxane A2 Synthesis in Aspirin-Treated PatientsWith AcuteMyocardial Infarction, " American Journal of Cardiology, vol. 104, no. 12, pp. 1618-1623, 2009.
32. S. M. Haffner, H. Miettinen, and M. P. Stern, "The homeostasis model in the San AntonioHeart Study, " Diabetes Care, vol. 20, no. 7, pp. 1087-1092, 1997.
33. G. V. R. Born, "Aggregation of blood platelets by adenosine diphosphate and its reversal, " Nature, vol. 194, no. 4832, pp. 927-929, 1962.
34. J. A. M. Relou, C. M. Hackeng, J.-W. N. Akkerman, and E. Malle, "Low-density lipoprotein and its effect on human blood platelets, " Cellular andMolecular Life Sciences, vol. 60, no. 5, pp. 961-971, 2003.
35. A. Moscardo, J. Valĺes, A. Latorre, I. Madrid, andM. T. Santos, "Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin: Biochemical regulatory mechanisms, " rombosis Research, vol. 131, no. 4, pp. e154-e159, 2013.
36. R. L. Silverstein, "Teaching an old dog new tricks: Potential antiatherothrombotic use for statins, " The Journal of Clinical Investigation, vol. 122, no. 2, pp. 478-481, 2012.
37. F. Violi, C. Calvieri, D. Ferro, and P. Pignatelli, "Statins as antithrombotic drugs, " Circulation, vol. 127, no. 2, pp. 251-257, 2013.
38. K. Schrör, P. Löbel, and E. Steinhagen-Thiessen, "Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia., " Eicosanoids, vol. 2, no. 1, pp. 39-45, 1989.
39. A. Notarbartolo, G. Davì, M. Averna et al., "Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia, " Arteriosclerosis, rombosis, and Vascular Biology, vol. 15, no. 2, pp. 247-251, 1995.
40. H. Osamah, R. Mira, S. Sorina, K. Shlomo, and A. Michael, "Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets, " British Journal of Clinical Pharmacology, vol. 44, no. 1, pp. 77-84, 1997.
41. L. Szapary, B. Horvath, Z. Marton et al., "Short-Term Effect of Low-Dose Atorvastatin on Haemorrheological Parameters, Platelet Aggregation and Endothelial Function in Patients with Cerebrovascular Disease and Hyperlipidaemia, " CNS Drugs, vol. 18, no. 3, pp. 165-172, 2004.
42. M. Labíos, M. Martínez, F. Gabriel, V. Guiral, E. Martínez, and J. Aznar, "Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry, " rombosis Research, vol. 115, no. 4, pp. 263-270, 2005.
43. T. Tekten, C. Ceyhan, E. Ercan, A.O. Onbasili, and C. Turkoglu, "The effect of atorvastatin on platelet function in patients with coronary artery disease, " Acta Cardiologica, vol. 59, no. 3, pp. 311-315, 2004.
44. P. D. Thompson, N. M. Moyna, C. MichaelWhite, K.M. Weber, S. Giri, and D. D. Waters, "The effects of hydroxy-methylglutaryl co-enzyme A reductase inhibitors on platelet thrombus formation, " Atherosclerosis, vol. 161, no. 2, pp. 301-306, 2002.
45. L. Puccetti, F. Santilli, A. L. Pasqui et al., "Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia, " Atherosclerosis, vol. 214, no. 1, pp. 122-128, 2011.
46. F. Santilli, P. Simeone, R. Liani, and G. Davì, "Platelets and diabetes mellitus, " Prostaglandins & Other Lipid Mediators, vol. 120, article no. 6120, pp. 28-39, 2015.